Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes.
A pilot trial of enzyme replacement with splenic and plasma alpha-galactosidase A (alpha-D-galactosidase; alpha-D-galactoside galactohydrolase, EC 3.2.1.22) isozymes was undertaken in two brothers with Fabry disease, an X-linked glycosphingolipid storage disease. Six unentrapped doses (2000 units/kg) of each isozyme were administered intravenously to the respective recipients during a 117-day period. The circulating half-life of the splenic isozyme was about 10 min, whereas that for the plasma isozyme was approximately 70 min. No immune response was detected by skin and immunodiffusion tests or by alterations in the maximal activity or clearance kinetics for either isozyme after successive administrations. After each dose of the splenic isozyme, the concentration of the accumulated circulating substrate, trihexosylceramide (globotriaosylceramide), decreased maximally (approximately 50% of initial values) in 15 min and returned to preinfusion levels by 2-3 hr. In marked contrast, injection of the plasma isozyme decreased the circulating substrate levels 50-70% by 2-6 hr; the concentrations gradually returned to preinfusion values by 36-72 hr.
D000328:Adult; D000795:Fabry Disease / Q000188:drug therapy* / Q000378:metabolism; D005696:Galactosidases / Q000627:therapeutic use*; D006207:Half-Life; D006801:Humans; D007527:Isoenzymes / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D007700:Kinetics; D008297:Male; D009928:Organ Specificity; D013154:Spleen / Q000201:enzymology*; D000519:alpha-Galactosidase / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*
D007527:Isoenzymes; D005696:Galactosidases; D000519:alpha-Galactosidase